Valuation: Becton, Dickinson and Company

Market Cap 49.57B 42.96B 40.28B 36.72B 69.1B 4,731B 70.21B 474B 185B 2,368B 186B 182B 7,899B P/E 2026 *
35.1x
P/E 2027 * 19.5x
Enterprise Value 65.45B 56.73B 53.18B 48.49B 91.24B 6,247B 92.7B 626B 244B 3,127B 246B 240B 10,431B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 3.22x
Free-Float
73.18%
Yield 2026 *
2.16%
Yield 2027 * 2.19%
Manager TitleAgeSince
Chief Executive Officer 53 27/01/2020
Director of Finance/CFO 44 04/12/2025
Compliance Officer - 31/01/2023
Director TitleAgeSince
Director/Board Member 75 23/09/2002
Director/Board Member 71 25/07/2010
Chairman 53 27/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.43% - - 49.57B
+0.32%+3.07%-14.01%+5.66% 193B
-0.20%+5.42%-2.51%+8.54% 116B
-1.32%-4.62%+6.52%+65.45% 59.16B
+0.17%+3.76%+38.21%+64.89% 55.75B
-0.88%+2.77%-7.14%-35.54% 49.57B
+0.75%+10.19%+14.41%-18.09% 34.52B
+0.23%+3.10% - - 31.22B
-1.74%-0.70%+40.59%-12.31% 24.36B
+1.55%+12.14%-3.22%+25.37% 24.25B
Average -0.11%+4.09%+9.11%+13.00% 65.26B
Weighted average by Cap. -0.07%+3.53%+1.05%+13.49%

Financials

2026 *2027 *
Net sales 19.29B 16.72B 15.68B 14.29B 26.89B 1,841B 27.32B 185B 72.06B 922B 72.43B 70.86B 3,074B 19.73B 17.1B 16.03B 14.62B 27.51B 1,883B 27.95B 189B 73.71B 943B 74.08B 72.48B 3,145B
Net income 1.44B 1.25B 1.17B 1.06B 2B 137B 2.03B 13.75B 5.37B 68.63B 5.39B 5.28B 229B 2.34B 2.03B 1.9B 1.73B 3.26B 223B 3.31B 22.38B 8.74B 112B 8.78B 8.59B 373B
Net Debt 15.88B 13.77B 12.91B 11.77B 22.14B 1,516B 22.5B 152B 59.33B 759B 59.64B 58.35B 2,532B 13.95B 12.09B 11.34B 10.34B 19.45B 1,332B 19.76B 133B 52.11B 667B 52.38B 51.24B 2,223B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
181.97USD
Average target price
194.42USD
Spread / Average Target
+6.84%

Quarterly revenue - Rate of surprise